ePrints

Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials

Lookup NU author(s): Dr Aaron Liew

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The novel oral anticoagulant drugs, comprising dabigatran, rivaroxaban, and apixaban, have emerged as compelling alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation, and low‑molecular‑weight heparin for thromboprophylaxis following hip and knee arthroplasty. Rivaroxaban has also been approved for treatment of venous thromboembolism. However, the role of these drugs for the management of patients with an acute coronary syndrome (ACS) is less certain. The purpose of this review was to summarize the randomized trials evaluating novel oral anticoagulants in patients with an ACS and consider the reasons why these drugs have not been incorporated into routine clinical practice. In addition, the situation involving rivaroxaban, which has been approved for use in patients with an acute coronary syndrome in Europe but not in North America, is discussed.

Publication metadata

Author(s): Liew A, Darvish-Kazem S, Douketis JD

Publication type: Review

Publication status: Published

Journal: Polskie Archiwum Medycyny Wewnetrznej

Year: 2013

Volume: 123

Issue: 11

Pages: 617-622

Print publication date: 04/11/2013

ISSN (print): 0032-3772

ISSN (electronic): 1897-9483

URL: http://www.pamw.pl/en/issue/article/24466582

PubMed id: 24466582

Share